BIIB - Biogen
146.47
| Index: | NDX, S&P 500 | P/E: | 13.23 | EPS (ttm): | 11.07 | Insider Own: | 0.71% | Shs Outstand: | 145.70M | Perf Week: | -2.37% |
| Market Cap: | 21.21B | Forward P/E: | 8.78 | EPS next Y: | 16.68 | Insider Trans: | -0.05% | Shs Float: | 144.68M | Perf Month: | -6.11% |
| Income(ttm): | 1.62B | PEG: | 3.31 | EPS next Q: | 3.42 | Inst Own: | 89.28% | Short Float: | 1.88% | Perf Quarter: | -25.20% |
| Revenue(ttm): | 9.23B | P/S: | 2.30 | EPS this Y: | 11.58% | Inst Trans: | 0.03% | Short Ratio: | 1.82 | Perf Half Y: | -35.36% |
| Book/sh: | 112.28 | P/B: | 1.30 | EPS next Y: | 1.54% | ROA: | 5.72% | Short Interest: | 2.72M | Perf Year: | -40.98% |
| Cash/sh: | 11.73 | P/C: | 12.48 | EPS next 5Y: | 4.00% | ROE: | 10.47% | 52W Range: | 145.24 - 268.30 | Perf YTD: | -43.40% |
| Dividend Est.: | - | P/FCF: | 10.89 | EPS past 5Y: | -18.05% | ROI: | 7.60% | 52W High: | -45.41% | Beta: | -0.06 |
| Dividend TTM: | - | Quick Ratio: | 0.80 | Sales past 5Y: | -4.53% | Gross Margin: | 67.77% | 52W Low: | 0.85% | ATR (14): | 3.93 |
| Dividend Ex-Date: | - | Current Ratio: | 1.26 | EPS Y/Y TTM: | 9.71% | Oper. Margin: | 22.96% | RSI (14): | 24.17 | Volatility: | 2.53% 2.33% |
| Employees: | 7570 | Debt/Eq: | 0.41 | Sales Y/Y TTM: | -3.98% | Profit Margin: | 17.50% | Recom: | 1.89 | Target Price: | 240.58 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.30 | EPS Q/Q: | 665.41% | Payout: | 0.00% | Rel Volume: | 3.86 | Prev Close: | 147.39 |
| Sales Surprise: | 1.29% | EPS Surprise: | 8.15% | Sales Q/Q: | -2.44% | Earnings: | Oct 30 BMO | Avg Volume: | 1.50M | Price: | 146.47 |
| SMA20: | -5.96% | SMA50: | -12.84% | SMA200: | -27.26% | Undervalued: 64.25% | Volume: | 5,775,355 | Change: | -0.62% | |
Graham Classic formula value: 164.02
(P/E=8 * 1g) Min value: 119.28
(current P/E * 2g) Max value: 211.03
Average value: 164.78
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.